Protocol Ledger

NCT03488251 · Phase II · TERMINATED

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Interventional Phase II clinical trial protocol NCT03488251 sponsored by Molecular Templates in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-20 Enrollment: 8 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03488251
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)8 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03488251
Protocol FieldVerified Registry Value
NCT IdentifierNCT03488251
Consolidated Lead SponsorMolecular Templates
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment8 participants (ACTUAL)
Registered Start Date2018-08-20
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI